Sickle Cell Anemia Treatment Safely Lowers Disease Burden in African Children

Newswise imageA daily hydroxyurea pill may bring relief for children living with the painful and deadly blood disease sickle cell anemia (SCA) in resource-challenged sub-Saharan Africa, where the disease is prevalent and health care is suboptimal. This is what a multinational clinical trial called REACH discovered when it tested daily hydroxyurea treatment in 606 children between the ages of 1 and 10 years old. Study data are published in the New England Journal of Medicine.

Source link

Related posts

Effects of hypoxic gas admixture in functionally univentricular patients awaiting Norwood palliation


Machine Learning To Predict Serious Bacterial Infections in Young Febrile Infants


Leaving your baby to 'cry it out' has no adverse effects on child development, study suggests


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World